Valrubicin
Valrubicin is a semisynthetic anthracycline analog of doxorubicin administered intravesically (directly into the bladder) for the treatment of BCG-refractory carcinoma in situ (CIS) of the bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. It intercalates into DNA and inhibits topoisomerase II while also disrupting cell membrane function, inducing apoptosis in bladder cancer cells. Its intravesical route minimizes systemic toxicity compared to systemic anthracyclines.
Moleküler Ağırlık
723,6000 g/mol
LogP
4,00
TPSA
215,00 Ų
Lipinski RO5
Başarısız
Terapötik Alanlar
Etki Mekanizması
Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.
2D Yapı
Cite this structure
Embed this structure
SMILES
CCCCC(=O)OCC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)C1)C(=O)c1c(OC)cccc1C3=O
InChI
InChI=1S/C34H36F3NO13/c1-4-5-9-21(40)49-13-20(39)33(47)11-16-24(19(12-33)51-22-10-17(27(41)14(2)50-22)38-32(46)34(35,36)37)31(45)26-25(29(16)43)28(42)15-7-6-8-18(48-3)23(15)30(26)44/h6-8,14,17,19,22,27,41,43,45,47H,4-5,9-13H2,1-3H3,(H,38,46)/t14-,17-,19-,22-,27+,33-/m0/s1
Molecular Formula
C34H36F3NO13
HBD / HBA
5 / 16
Döndürülebilir Bağlar
11
Ağır Atomlar
51
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
Valrubicin is a semisynthetic anthracycline analog of doxorubicin administered intravesically (directly into the bladder) for the treatment of BCG-refractory carcinoma in situ (CIS) of the bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. It intercalates into DNA and inhibits topoisomerase II while also disrupting cell membrane function, inducing apoptosis in bladder cancer cells. Its intravesical route minimizes systemic toxicity compared to systemic anthracyclines.
Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.
Yes, Valrubicin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1096885. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 454216. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="valrubicin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/valrubicin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/valrubicin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/valrubicin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="valrubicin"></drugfyi-drug>